Patient demographics
glioblastoma, CED
GLIOBLASTOMA
Fifteen patients with histologically confirmed recurrent glioblastoma were recruited from 3 centers (Neurological Institute “Carlo Besta”, Erasmus Medical Center, and Amsterdam Medical Center) between July 2017 and October 2019. They were assigned to five cohorts of three patients, receiving increasing doses of hrBMP4 (0·5, 1·5, 4, 9, and 18 mg) via CED and included in the statistical analyses. Patient characteristics are shown in Supplementary Tables 